Oxazole, 5-ethyl-2-propyl

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Oxazole, 5-ethyl-2-propyl
• 英文别名: 5-ethyl-2-propyl-1,3-oxazole
• 化学式: C₈H₁₃NO
• 分子量: 139.19
• InChiKey: QQCWDOQKZRFUKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES BICYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2009010530A1

  公开（公告）日：2009-01-22

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇（PI）3-激酶抑制剂化合物，其药用盐及其前药；新化合物的组合物，可以单独使用或与至少一种额外治疗剂联合使用，携带药用载体；新化合物的用途，可以单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗由生长因子、蛋白质丝氨酸/苏氨酸激酶和磷脂激酶异常活性所特征化的增殖性疾病。
• Organic Compounds
  申请人：Budd Emma

  公开号：US20080319033A1

  公开（公告）日：2008-12-25

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and X have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I中R1、R2、R3、R4和X的自由或盐形式化合物，其含义如规范所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• PI3 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Ni Zhi-Jie

  公开号：US20100075965A1

  公开（公告）日：2010-03-25

  Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.

  磷脂酰肌醇（PI）3激酶抑制剂化合物及其药学上可接受的盐和前药；新化合物的组合物，可以单独使用或与至少一种其他治疗药物结合，与药学上可接受的载体；以及新化合物的用途，可以单独使用或与至少一种其他治疗药物结合，用于预防或治疗增殖性疾病，其特征是生长因子、蛋白质丝氨酸/苏氨酸激酶、磷脂酰肌醇激酶、G蛋白偶联受体和磷酸酶的异常活性。
• Thiazol-2-yl organic compounds
  申请人：Novartis AG

  公开号：EP2357179A1

  公开（公告）日：2011-08-17

  Compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4 and X have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  其中 R1、R2、R3、R4 和 X 的含义如说明书所示，游离或盐形式的式 (I) 化合物可用于治疗由磷脂酰肌醇 3- 激酶介导的疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的工艺。
• US7754746B2
  申请人：——

  公开号：US7754746B2

  公开（公告）日：2010-07-13